肝动脉灌注化疗治疗晚期肝细胞癌的毒性与疗效（综述）
Toxicity and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma (Review).
作者信息
Ueda Hiroki, Fukuchi Hiroko, Tanaka Chigusa
机构信息
Department of Chemotherapy, Wakayama Medical University Oncology Center, Wakayama City, Wakayama 641-8509, Japan.
出版信息
Oncol Lett. 2012 Feb;3(2):259-263. doi: 10.3892/ol.2011.469. Epub 2011 Nov 2.
Abstract
The prognosis of advanced hepatocellular carcinoma (HCC) remains poor, particularly for patients with portal vein tumor thrombosis. Chemotherapy is one of the most significant treatment options for patients with advanced HCC not indicated for hepatic resection, percutaneous ablation and transcatheter arterial chemoembolization. Systemic chemotherapy does not play a central role in the treatment of HCC due to the issue of low sensitivity for chemotherapeutic agents and the difficulties in administering a sufficient dose due to chronic liver dysfunction. Therefore, patients with advanced HCC are usually treated with hepatic arterial infusion chemotherapy (HAIC), which is increasingly used as an approach to advanced HCC in Japan. HAIC provides moderate therapeutic efficacy and survival benefit with substantially tolerable toxicity profiles in patients with advanced HCC.
摘要
晚期肝细胞癌（HCC）的预后仍然很差，尤其是对于伴有门静脉癌栓的患者。化疗是不适用于肝切除、经皮消融和经动脉化疗栓塞的晚期HCC患者最重要的治疗选择之一。由于化疗药物敏感性低以及慢性肝功能障碍导致难以给予足够剂量，全身化疗在HCC治疗中并不起核心作用。因此，晚期HCC患者通常接受肝动脉灌注化疗（HAIC），在日本，HAIC越来越多地被用作晚期HCC的一种治疗方法。HAIC在晚期HCC患者中具有适度的治疗效果和生存获益，且毒性反应基本可以耐受。
相似文献
1
Toxicity and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma (Review).
Oncol Lett. 2012 Feb;3(2):259-263. doi: 10.3892/ol.2011.469. Epub 2011 Nov 2.
2
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan.
Cancers (Basel). 2012 Feb 21;4(1):165-83. doi: 10.3390/cancers4010165.
3
Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.
Cardiovasc Intervent Radiol. 2020 Jul;43(7):996-1005. doi: 10.1007/s00270-019-02406-3. Epub 2020 Jan 23.
4
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.
Cancer. 2002 Aug 1;95(3):588-95. doi: 10.1002/cncr.10694.
5
Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Cancer Chemother Pharmacol. 2018 Sep;82(3):469-478. doi: 10.1007/s00280-018-3638-0. Epub 2018 Jul 7.
6
Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.
J Gastroenterol Hepatol. 2018 Oct;33(10):1780-1786. doi: 10.1111/jgh.14152. Epub 2018 May 10.
7
Advanced hepatocellular carcinoma with hepatic vein tumor thrombosis and renal dysfunction after hepatic arterial infusion chemotherapy effectively treated by liver resection with active veno-venous bypass: report of a case.
BMC Cancer. 2016 Sep 1;16(1):705. doi: 10.1186/s12885-016-2749-4.
8
Hepatic Arterial Infusion Chemotherapy Followed by Lipiodol Infusion for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Single-Center Experience.
Medicina (Kaunas). 2021 Jul 30;57(8):779. doi: 10.3390/medicina57080779.
9
A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma.
Korean J Hepatol. 2010 Dec;16(4):355-61. doi: 10.3350/kjhep.2010.16.4.355.
10
Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma.
Asia Pac J Clin Oncol. 2010 Jun;6(2):80-8. doi: 10.1111/j.1743-7563.2010.01287.x.
引用本文的文献
1
All You Need to Know About TACE: A Comprehensive Review of Indications, Techniques, Efficacy, Limits, and Technical Advancement.
J Clin Med. 2025 Jan 7;14(2):314. doi: 10.3390/jcm14020314.
2
Hepatic arterial infusion chemotherapy combined with sorafenib versus sorafenib alone for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Clin J Gastroenterol. 2023 Dec;16(6):793-802. doi: 10.1007/s12328-023-01860-4. Epub 2023 Sep 23.
3
A review of applying transarterial chemoembolization (TACE) method for management of hepatocellular carcinoma.
J Family Med Prim Care. 2021 Oct;10(10):3553-3560. doi: 10.4103/jfmpc.jfmpc_2347_20. Epub 2021 Nov 5.
4
Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
Biomed Res Int. 2021 Jul 14;2021:6670367. doi: 10.1155/2021/6670367. eCollection 2021.
5
Time to stop using hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma?-the SCOOP-2 trial experience.
Ann Transl Med. 2020 Nov;8(21):1340. doi: 10.21037/atm-2020-96.
6
Real world clinical practice in treating advanced hepatocellular carcinoma: When East meets West.
PLoS One. 2020 Mar 12;15(3):e0230005. doi: 10.1371/journal.pone.0230005. eCollection 2020.
7
Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A.
World J Surg Oncol. 2019 Aug 15;17(1):143. doi: 10.1186/s12957-019-1685-6.
8
5H-benzo[h]thiazolo[2,3-b]quinazolines ameliorate NDEA-induced hepatocellular carcinogenesis in rats through IL-6 downregulation along with oxidative and metabolic stress reduction.
Drug Des Devel Ther. 2017 Oct 13;11:2981-2995. doi: 10.2147/DDDT.S143075. eCollection 2017.
9
Dendrimer-doxorubicin conjugates exhibit improved anticancer activity and reduce doxorubicin-induced cardiotoxicity in a murine hepatocellular carcinoma model.
PLoS One. 2017 Aug 22;12(8):e0181944. doi: 10.1371/journal.pone.0181944. eCollection 2017.
10
Vastatin, an Endogenous Antiangiogenesis Polypeptide That Is Lost in Hepatocellular Carcinoma, Effectively Inhibits Tumor Metastasis.
Mol Ther. 2016 Aug;24(8):1358-68. doi: 10.1038/mt.2016.56. Epub 2016 Mar 10.
本文引用的文献
1
Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.
Expert Opin Pharmacother. 2011 Feb;12(2):303-13. doi: 10.1517/14656566.2011.546346.
2
Hepatic arterial infusion therapy with a fine powder formulation of cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Jpn J Clin Oncol. 2011 Jan;41(1):69-75. doi: 10.1093/jjco/hyq145. Epub 2010 Aug 5.
3
Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma.
Oncology. 2010 Jul;78 Suppl 1:148-53. doi: 10.1159/000315244. Epub 2010 Jul 8.
4
Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
Anticancer Drugs. 2010 Mar;21(3):326-32. doi: 10.1097/CAD.0b013e3283350e26.
5
Transcatheter arterial infusion chemotherapy with cisplatin-lipiodol suspension in patients with hepatocellular carcinoma.
J Gastroenterol. 2010;45(1):60-7. doi: 10.1007/s00535-009-0109-8. Epub 2009 Aug 5.
6
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.
7
Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies.
Hepatology. 2009 Feb;49(2):453-9. doi: 10.1002/hep.22648.
8
Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma.
Hepatol Res. 2008 May;38(5):474-83. doi: 10.1111/j.1872-034X.2008.00338.x.
9
Hepatic arterial infusion chemotherapy with epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis.
Oncology. 2007;72(3-4):188-93. doi: 10.1159/000112805. Epub 2007 Dec 20.
10
Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma.
Hepatogastroenterology. 2007 Mar;54(74):518-21.
Zotero 插件